The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study

Trial Details

NCT ID

NCT06125080

Phase

PHASE2

Sponsor

Huihua Xiong

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

• Utidelone
• Tirelizumab
• Bevacizumab

Locations (sample)

• Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

• Patients voluntarily participated in the study, signed the informed consent, and had good compliance; Female patients aged 18-70; TNBC confirmed by…
• Neutrophil absolute value ≥1.5×109/L, platelet ≥100×109/L, hemoglobin concentration ≥9g/dL);
• Liver function test (aspartate aminotransferase and glutamic aminotransferase ≤2.5×ULN, bilirubin ≤1.5×ULN; In the presence of liver metastasis, AS…
• Renal function (serum creatinine ≤1.5×ULN, or creatinine clearance (CCr)≥60ml/min);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.